Effective delivery of tumor antigens to APCs is one of the key steps for eliciting a strong and durable immune response to tumors. Several cancer vaccines have been evaluated in clinical trials, based on soluble peptides, but results have not been fully satisfactory. To improve immunogenicity particles provide a valid strategy to display and/or incorporate epitopes which can be efficiently targeted to APCs for effective induction of adaptive immunity. In the present review, we report some leading technologies for developing particulate vaccines employed in cancer immunotherapy, highlighting the key parameters for a rational design to elicit both humoral and cellular responses.
VLPs and particle strategies for cancer vaccines / Ungaro, Francesca; Conte, Claudia; Quaglia, Fabiana; Maria Lina, Tornesello; Franco M., Buonaguro; Luigi, Buonaguro. - In: EXPERT REVIEW OF VACCINES. - ISSN 1476-0584. - 12:10(2013), pp. 1173-1193. [10.1586/14760584.2013.836909]
VLPs and particle strategies for cancer vaccines
UNGARO, FRANCESCA;CONTE, CLAUDIA;QUAGLIA, FABIANA;
2013
Abstract
Effective delivery of tumor antigens to APCs is one of the key steps for eliciting a strong and durable immune response to tumors. Several cancer vaccines have been evaluated in clinical trials, based on soluble peptides, but results have not been fully satisfactory. To improve immunogenicity particles provide a valid strategy to display and/or incorporate epitopes which can be efficiently targeted to APCs for effective induction of adaptive immunity. In the present review, we report some leading technologies for developing particulate vaccines employed in cancer immunotherapy, highlighting the key parameters for a rational design to elicit both humoral and cellular responses.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
